NASDAQ
Madrigal Pharmaceuticals, Inc. (MDGL) has a price/sales ratio of 13.63x as of Friday, May 22, 2026. This represents a 49.63% increase compared to its 12-month average of 9.11x. The price-to-sales ratio evaluates a company's stock price relative to its revenue, useful for valuing companies with little or no earnings.
No price data available for this timeframe.